M. Delcroix (Leuven, Belgium), J. A. Barbera (Barcelona, Spain)
Prognostic value of periodic breathing in primary pulmonary hypertension (PPH)
C. Pison, N. Chouri, F. Felix, B. Coltey, R. Hamidfar, J. L. Pepin (Grenoble, France)
|   |
Bronchoalveolar lavage (BAL) as a diagnostic tool in pulmonary hypertension: occult alveolar haemorrhage is a common feature of pulmonary veno-occlusive disease (PVOD)
A. Rabiller, O. Sitbon, F. Parent, V. Ioos, X. JAIS, A. Hamid, G. Garcia, A. Resten, S. Maitre, D. Musset, F. Capron, G. Simonneau, M. Humbert (Clamart, France)
| |
Association between portopulmonary hypertension and hepatopulmonary syndrome in cirrhotics, candidates to hepatic transplantation
E. Garcia, A. I. Zille, J. S. Moreira, A. B. Brandao (Porto Alegre, Brazil)
| |
Long-term haemodynamic response in patients with pulmonary hypertension inhaling iloprost (AIR-2 STUDY)
J. Behr, S. Nikkho, M. Borst, R. Ewert, M. Hoeper, A. Meyer, H. Olschewski, W. Seeger (Berlin, Germany)
| |
Effect of intravenous epoprostenol on quality of life in pulmonary arterial hypertension
C. Hernandez, S. Santos, J. Roca, E. Sala, F. Burgos, R. Rodriguez-Roisin, J. A. Barbera (Barcelona, Palma de Mallorca, Spain)
| |
A clinical comparison of slow- and rapid-escalation treprostinil dosing regimens in patients with pulmonary arterial hypertension (PAH)
N. Skoro-Sajer, E. Harja, I. M. Lang, M. P. Kneussl, W. Gin Sing, J. S. R. Gibbs (Vienna, Austria; London, United Kingdom)
| |
Bosentan in pulmonary arterial hypertension associated with HIV infection
O. Sitbon, V. Gressin, R. Speich, M. Opravil, P. MacDonald, D. Cooper, M. Rainisio, M. Humbert, G. Simonneau (Clamart, France; Zurich, Switzerland; Sydney, Australia)
| |
One hour alteplase infusion plus low molecular weight heparin versus heparin alone in pulmonary embolism
C. Jerjes-Sanchez, S. Villarreal, A. Ramirez-Rivera, R. Arriaga, F. Rangel (Monterrey, Mexico City, Mexico)
| |